Antibody therapeutics discovery: Focus on bispecifics and immune checkpoint modulators
Development of novel antibodies and more powerful therapeutic combinations for immunotherapy is an intense area of focus. However, for difficult and/or conserved targets, finding antibodies with unique functionality, and generating early proof of concept pose challenges to the development of novel antibody therapeutics. Symphogen’s approach to discovery and development of potent antibody combinations for cancer immunotherapy using different species, including chicken, will be presented. Examples from our clinical pipeline will be shown.